Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 17/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | GIPR | P48546 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718183 | 0.93 | GCG (0.45) | GCGGLP1RGCGRGIPRCYP2D6 | |
| SCHEMBL718024 | 0.85 | GCG (0.43) | GCGGLP1RGCGRGIPRTEAD4 | |
| SCHEMBL719091 | 0.84 | MEN1 (0.46) | GCGGLP1RGCGRGIPR | |
| SCHEMBL718334 | 0.81 | GCG (0.40) | GCGGLP1RGCGRGIPR | |
| SCHEMBL720544 | 0.81 | GCG (0.46) | GCGGLP1RGCGRGIPRCYP2D6 | |
| SCHEMBL3399101 | 0.80 | TEAD4 (0.36) | GCGTEAD4 | |
| SCHEMBL721199 | 0.78 | NPC1 (0.48) | GCGGLP1RGCGRGIPR | |
| SCHEMBL719959 | 0.78 | GCG (0.46) | GCGGLP1RGCGRGIPR | |
| SCHEMBL3397932 | 0.78 | GCG (0.48) | GCGGLP1RGCGRGIPR | |
| SCHEMBL721727 | 0.77 | NPC1 (0.47) | GCGGLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GLP1R 5/4885GCGR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.